rs142143310
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBP6
The NM_014476.6(PDLIM3):c.715G>A(p.Asp239Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000339 in 1,611,612 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D239G) has been classified as Uncertain significance.
Frequency
Consequence
NM_014476.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
PDLIM3 | NM_014476.6 | c.715G>A | p.Asp239Asn | missense_variant | 6/8 | ENST00000284767.12 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
PDLIM3 | ENST00000284767.12 | c.715G>A | p.Asp239Asn | missense_variant | 6/8 | 5 | NM_014476.6 | A1 | |
ENST00000671042.1 | n.617C>T | non_coding_transcript_exon_variant | 4/4 |
Frequencies
GnomAD3 genomes AF: 0.000414 AC: 63AN: 152150Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000731 AC: 182AN: 249114Hom.: 1 AF XY: 0.000660 AC XY: 89AN XY: 134802
GnomAD4 exome AF: 0.000332 AC: 484AN: 1459462Hom.: 1 Cov.: 32 AF XY: 0.000337 AC XY: 245AN XY: 726114
GnomAD4 genome AF: 0.000414 AC: 63AN: 152150Hom.: 0 Cov.: 32 AF XY: 0.000377 AC XY: 28AN XY: 74332
ClinVar
Submissions by phenotype
not provided Benign:3
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Aug 08, 2017 | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2023 | PDLIM3: BP4, BS1 - |
Likely benign, no assertion criteria provided | provider interpretation | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Jan 18, 2017 | Testing for our patient was done at GeneDx. Given the lack of case data, the variant's frequency in general population databases and limited gene level evidence, we consider this variant likely benign, and we do not feel it is suitable for assessing risk in healthy relatives ("predictive genetic testing"). Gene Level Evidence for PDLIM3 and cardiomyopathy There is limited evidence that variants in the PDLIM3 gene cause cardiomyopathy. Variants in the PDLIM3 gene have rarely been reported in patients with hypertrophic and dilated cardiomyopathy, identified through candidate gene screening of DCM and HCM patient cohorts. It has also been proposed that PDLIM3 splicing mutations may play a role in myotonic dystrophy. Variant level evidence There are no published reports of this variant in any cases of cardiomyopathy, arrhythmia, or sudden death. There is no case data. In silico analysis do not agree on the predicted effect of the variant. The aspartic acid at codon 239 is not well conserved across species, suggesting variation at this position may be tolerated. There are no other variants reported as pathogenic in ClinVar. The variant is present in the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org/), which currently includes variant calls on >66,000 unrelated individuals of African, Asian, European, Latino, and Ashkenazi descent. Specifically, the variant was observed in 49 of 33,236 individuals of European descent (MAF=0.07%), 5 of 5780 individuals of Latino descent (MAF=0.04%), 2 of 5170 individuals of African descent (MAF=0.02%), and 1 of 4303 individuals of East Asian descent (MAF=0.01%). The phenotype of those individuals is not publicly available. The dataset is comprised of multiple cohorts, some of which were recruited from the general population, others were enriched for common cardiovascular disease. The variant was reported online in 178 of 140,188 individuals in the Genome Aggregation Consortium Dataset (gnomAD; http://gnomad.broadinstitute.org/), which currently includes variant calls on >140,000 unrelated individuals of African, Asian, European, Ashkenazi, Latino descent. Specifically, the variant was observed in 135 of 5081 individuals of Ashkenazi Jewish descent (MAF=1.3%). Of note, one of the Ashkenazi Jewish individuals was homozygous for this variant. The variant was also present in 6 of 9466 individuals of East Asian descent (MAF=0.03%), 10 of 19236 individuals of Latino descent (MAF=0.02%), 12 of 63,381 individuals of European descent (MAF=0.01%), and 2 of 12,931 individuals of African descent (MAF=0.01%). The phenotype of those individuals is not publicly available. The dataset is comprised of multiple cohorts, some of which were recruited from the general population, others were enriched for common cardiovascular disease. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 11, 2015 | Variant classified as Uncertain Significance - Favor Benign. The p.Asp239Asn var iant in PDLIM3 has not been previously reported in individuals with cardiomyopat hy, but has been identified 0.07% (49/66472) of European chromosomes by the Exom e Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs14214331 0). Aspartic acid (Asp) at position 239 is not conserved in evolution and 3 mamm als (prairie vole and 2 bats) have an asparagine (Asn) at this position, suggest ing that this change may be tolerated. In summary, while the clinical significan ce of the p.Asp239Asn variant is uncertain, the presence of the variant amino ac id in other mammals combined with the frequency in the general population sugges ts that it is more likely to be benign. - |
Primary dilated cardiomyopathy;C0007194:Hypertrophic cardiomyopathy Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 06, 2024 | - - |
Familial cardiomyopathy Other:1
not provided, no classification provided | phenotyping only | GenomeConnect, ClinGen | - | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at